Make your drug development a success! • PhInc. Modeling

They trust us

John DiBella

President, Lancaster Division - Simulations Plus, Inc. (NASDAQ: SLP)

Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity.

Sakina Sayah-Jeanne

Senior Director, Translational R&D - Da Volterra

PhinC has been accompanying Da Volterra for several years on PBPK Modelling activities. Our collaboration, based on mutual trust, has already been very fruitful and has allowed Da Volterra to gain precious knowledge on its product under development. Da Volterra enjoys working with PhinC and will continue to do so in the years to come, leaning from its expertise.

Agnes Hemon

Preclinical and P.K clinical Officer - HRA Pharma

PhinC is one of HRA Pharma’s valuable partners for pharmacokinetic studies. From just an advice to modelling, we know we can trust them to efficiently support and carry out our projects.

Olivier Lacombe

Head of Pharmacokinetics - Inventiva

Inventiva and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs.

Antoine Tarral

Head of HAT Clinical Programme - DNDi

The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program.

Your PK Modeling & Simulation Partner!

News

[Webinar]: AI in drug development

News

Modeling & Simulation Strategies Must Be Integrated into Clinical Development

Careers

Discover our job offers!

They trust us